Berkshire Hathaway Energy Company et al. v. MES, Inc.

WHOOP, Inc.vsOmni MedSci, Inc.

WHOOP petitions the PTAB to invalidate claims 6, 11‑12, 14, and 18 of Omni MedSci’s ’533 wearable optical sensor patent, asserting obviousness over Lisogurski combined with Carlson, Walker, or Tam and invoking collateral estoppel from prior IPRs.

REC Solar Holdings AS et al.vsMaxeon Solar PTE. Ltd.

REC Solar seeks cancellation of claims 9‑12 of Maxeon’s 8,222,516 solar‑cell patent, asserting obviousness over several prior‑art references and invoking collateral estoppel from earlier PTAB rulings.

Databricks, Inc.vsByteWeavr LLC

Databricks and ByteWeavr have reached a settlement and jointly moved to terminate the pending IPR over patent 7,949,752. The Board is asked to grant the motion based on efficiency and the lack of opposition.

Amphenol CorporationvsCredo Technology Group Ltd.

Amphenol and Credo have settled their IPR dispute over U.S. Patent 10,877,233 and jointly request that the settlement agreement be kept confidential as the proceeding is terminated.

Aquestive Therapeutics, Inc.vsIono Pharma, LLC

Aquestive Therapeutics seeks Director Review of the PTAB’s denial of institution for its IPR against Iono Pharma’s epinephrine prodrug patent. Iono Pharma argues the request fails statutory standards and should be denied.